重组L-门冬酰胺酶前体脂质体对HL-60细胞生长的影响  

Effects of recombinant L-asparaginase proliposomes on the growth of HL-60 cells

作　　者：王弘[1] 吴梧桐[2] 顾学裘[3] 

机构地区：[1]解放军总医院临床药学研究室,北京100853 [2]中国药科大学生物制药学院,南京210009 [3]沈阳药科大学药学院,沈阳110015

出　　处：《中国新药杂志》2005年第8期1004-1006,共3页Chinese Journal of New Drugs

摘　　要：目的:研究L-门冬酰胺酶(L-ASNase)脂质体对体外培养的人早幼粒细胞白血病(HL-60)细胞活性的影响。方法:实验分3组:对照1组加入新鲜RPMI1640培养液倍比稀释的空白脂质体;对照2组加入L-ASNase(终浓度分别为2.5,5,10,20和40μg·mL-1);实验组加入L-ASNase脂质体(前体脂质体水合而得,终浓度分别为2.5,5,10,20和40μg·mL-1)。MTT法测定细胞存活率,电镜观察细胞形态学,流式细胞仪检测肿瘤细胞周期的改变。结果:L-门冬酰胺酶脂质体(经前体脂质体水合而得)组HL-60细胞的G0/G1期细胞量明显增加,S期的细胞明显减少;增殖指数(PI)显著下降;HL-60细胞凋亡比例显著增多。结论:L-门冬酰胺酶脂质体抑制HL-60细胞的繁殖,可能与抑制细胞的S期有关。Objective：To investigate the effects of L-asparaginase（L-ASNase） liposomes on growth of HL-60 cells in vitro. Methods： Three groups of HL-60 cells cultures were manipulated, one supplementing fresh RPMI1640 culture medium plus diluted liposomes, one supplementing L-ASNase （final concentrations of 2.5,5, 10, 20 and 40μg·mL^-1, respectively） and one mixing with L-ASNase proliposomes （final concentrations of 2.5,5,10,20 and 40μg·mL^-1, respectively）. The antiproliferation activities of L-ASNase liposomes were evaluated on HL-60 cells by means of MTT vital staining. The morphological changes of L-ASNase liposomes on HL-60 cells were observed under transmission electron microscope. The cell division cycle affected by L-ASNase liposomes was assessed by a flow cytometer. Results： The HL-60 ceils culturing with the L-ASNase liposomes were mostly in the resting phase G0/G1 and less in the phase S. The flow cytometric analyses showed that the exposure to L-ASNase liposomes for 24 h reduced the proliferation index of HL-60 cells. Under electronic microscope, the HL-60 cells exposed to L-ASNase liposomes for 24 h displayed morphological changes of apoptosis, more heterochromosome and less somatic chromosome. Conclusion： L- ASNase liposomes inhibited the proliferating activities of the HL-60 cells by the development arrest of the S phase in the cells.

关 键 词：L-门冬酰胺酶 前体脂质体 HL-60细胞 细胞周期 

分 类 号：R979.1[医药卫生—药品] R965.1[医药卫生—药学]